Theresa Lambe & Sarah Gilbert

Liverpool School of Tropical Medicine

Serum from 10 convalescent patients 5ml

https://doi.org/10.12688/wellcomeopenres.16522.1

Sumathi Sivapalasingam

Production of therapeutic antibodies from B cells

Testing against CDC/PHE primer/probe set

Develop an elisa-based immunoassay for detecting Covid-19 antibodies

100ul convalescent plasma/serum. 12.06.2020 1ml WO

We (NIHR Unit Tackling Infections to benefit Africa (TIBA) at the University of Edinburgh) are funded by the UK National Institutes of Health Research through the Global Health Research Fund. As part of this funding we were instructed to use some of the funding for research to respond to national of global health emergencies

Diagnostic COVID-19 peptides in collaboration with University of Edinburgh

PEPperPrint: internal funding UoE: NIHR

Identify B cells that secrete neutralizing antibodies against the SARS-CoV-2 virus.

Partial validation of 3 commercially available lateral flow cassettes.

Approved for diagnostic evaluation platform

Brighton and Sussex Medical School

Expansive peptide array to detect antibody responses spanning full proteome

10-20ul serum. Recovered patients. Clinical course must be known. ~ 100 samples.

Health Protection Scotland

Validate a serological ELISA assay for immunological response curve

Serum samples at least 500ul. Helpful if it's pared as acute and convalescent. N=50.

Diagnostic serology assay for use in hospitals and blood testing insitutions.

5ml plasma or serum samples. Preferably dozens

Determine the plasma proteome in COVID-19 patients

Understanding the pathogenesis through standard lab techniques like ELISAs

Serum and Plasma. 1ml vial of urine and oral swabs if available. Male patients moderate and severe

MRC/UKRI rolling funding call

Quantify lipids and metabolites using mass spectrometry lipidomics/ Steroid analyses

Plasma - 100µl from 600 patients - 12.06.2020 request changed to 500ul for steroid analyes, 60 severe, 60 mild, 80 unifected (unavailable)

Validate the multivariable prognostic model established in Chinese cohorts. Compare prognostic variable with circulating histones.

Development and selection of antigens for diagnostics and vaccine candidates. Establish ELISAs using antigen proteins

2ml convalescent serum. 6+ patients.

Core BBSRC funds. University of Kent funds.

Approved for diagnostic evaluation platform

Super-neutralising antibodies pull-down using Spike protein conjugated beads

Host genotyping for IFNL4 for COVID-19 patients.

Stratification of COVID-19 patients using 2 established metabolic pathway panels.

N=500 X 100uL of plasma or serum

MRC fellowship and existing industry collaborations

British HIV Association Group

Investigate infection rate and disease course of COVID-19 in HIV patients.

Periodic reports of HIV positive patients. Access to immunology, serology and PCR results. Every 1-3 months. Samples: Serum/plasma 500ul from as many HIV-positive patients as possible.

RNA seq to investigate differential gene expression between patient groups (eg age, sex, hypertension treatment and recovery)

RNA from Oracol or viral throat swabs. RNA or materials from 300 patietns.

University College London

Machine learning to identify T-cell receptor signature that predicts clinical outcomes.

Blood RNA (600ng extracted from tempus tubes) Day 1,3,9 and 28. 300 longitudinal patients.

UKRI funding application depending on sample access

Phenotypic and functional T-cell responses to COVID-19 vaccine targets and identify metabolism differences in Type 2 diabetes patients.

4 million PBMCs from 50 COVID-19 patients with and without Type 2 diabetes at Day 1 and Day 28 (where available). Linked patient metadata including age, gender, disease severity, supportive care received, trial treatments and outcome. Matched for age, gender and disease severity at Day 1.

Salary and lab running costs covered by existing grants. Applying for Diabetes UK COVID-19 Rapid Response for further funding.

Infrared spectroscopy-based test for COVID-19 risk stratification and immunity

50ul serum from day 1, 9 and 28 of 200 patients. If not possible, Day 1 and 28 possible.

UKRI, CSO and others for validation phase. Algorithm training can start without funding.

University of Liverpool and Liverppol University Hospitals NHS Foundation Trust

Douglas B Kell (PI) Andrew S Davison

Untargeted metabolomics of serum samples during COVID-19. Longitudinal sampling to asses relationships between metabolites and infection, disease progression, severity and outcome. Samples will be analysed using high-resolution mass spectrometry.

Surplus serum and anonymised metadata (age, sex, disease status and other clinical information) collected in Liverpool Clinical Laboratories. Each sample requires a minimum volume of 150ul.

Measuring INF-alpha in COVID-19 patients using an ultrasensitive digital ELISA assay

Funding in place for 100 samples. Funding pending for 1000+ samples.

https://doi.org/10.1101/2020.10.08.20209411

Investigating neurological disease in COVID-19 through clinical features, risk factors and analysis of CSF and sera to understand disease mechanisms.

Data - analysis of patient data with features suggestive of neurological disease. Determine risk factors for neurological disease. If protocols and ethics allow, detailed questionnaire to be sent to research sites and contact patients for more info re outcome. Samples- CSF (2ml - min of 100ul doable) and serum (2ml). Unsure how many samples may be available.

Funding from NIHR HPRU in EZI

Elucidate host genetic determinants and develop predictive models for COVID-19 severity by using phenotypic data.

All phenotypic data (biochemical, hematological, immunological data), host genotype data, RNA seq data (D1,3,9 and 28). Viral sequencing data for host genetics and viral sequence.

Quebec provincial government and Fonds de recherche du Quebec - Sante.

Approve for collaboration

Identify vulnerable groups at risk of disease. DHSC letter of support.

Clinical data collected on admission, daily and outcome forms. Differences in outcomes based on ethnicity, co-morbidities, obesity and socio-economic status.

Investigate DAMPs assays as prognostic marker. Drug treatments that block the action of DAMPs. Clarify role of gut ACE2 expression and transmissibility. Understanding gut microbiome and whether clinial outcome can be predicted from GI microbiome data.

Serum and plasma (5mls) - 200 patients (100 ICU vs 100 non-ICU). Stools (5-10ml) 1000 patients with associated clinical data (cluster 3 - with GI symptoms vs non-GI symptoms). Clinical data - 1000 patients stratified by disease severity and clinical phenotype - with or without diarrhea.

Helmsley Trust, ERC, Scot Government RESAS, BBSCRC, and funds form Scottish Senior Fellowship.

Lance Turtle Julian Hiscox

Determining the ability of culturing SARS-CoV-2 virus using respiratory tract swabs.

20-50 respiratory tract swabs from patients with severe COVID-19 and mild/moderate disease respectively.

Highlighting severity of COVID-19 to better inform Brazilian population

Clinical data - demographics, details regarding presentation, admission and clinical outcomes.

Zoltan Takats James Kinross Lauren Ford *In combination with Request 47 Dumas

Ambient mass spectrometry techniques for metabolite biomarkers of COVID-19 status and host immune response and a protease assay for a rapid, point-of-care test.

Combined nose and throat swabs, otherwise a throat swab or nasopharyngeal swab alone. As many as possible.

Imperial Biomedical Research Centre.

Marc-Emmanuel Dumas Julian Griffin Zoltan Takats Peter Openshaw *In combination with Request 43 Takats

Metabolomic profiling of COVID-19 to improve mechanistic understanding, provide insights into secondary biological effects and further develop prognostic markers.

All 650 patients at 4 timepoints - 2600 samples. Plasma (or serum) 375ul per sample. Urine 275ul per sample. Stool 500mg per sample. Swab metabolomics - Prof Takats application (Request 43)

Imperial Biomedical Research Centre.

University of Liverpool University of Sheffield University of Oxford

Lance Turtle Paul Klenerman Thusan DeSilva Susie Dunachie Ellie Barnes Alex Mentzer

Phenotypic and functional T-cell response to SARS-CoV-2 including vaccine targets. Greater capacity and samples than original ISARIC-4C aims of characterising the immune response.

30-40 million PBMCs from all donors sampled. Final sample sizes to be determined as part of the ISARIC-4C follow up WP9.

Internally funded by University of Liverpool and University of Oxford.

AI algorithms to rapidly identify COVID-19 illness at the front-door of hospitals.

Essential data: Admission blood tests - FBC, U&Es, LFTs, CRP, Clotting function, Microbiology, SARS-CoV-2 results, influenza results (where tested) admission observations (if available). Desirable: Single set of pre-morbid blood tests values for the same parameters.

Roberta Forlano Mark Thurz Pinelopi Manousou Benjamin Mullish

Risk factors of COVID-19 patients with non-alcoholic fatty liver disease

Clinical data - demographics, blood test results, details regarding presentation, admission and clinical outcomes.

Imperial Biomedical Research Centre.

Development of a multifactorial RSM tool to improve outcomes and triaging of patients

Raw data used to create survival from onset plot and Symptoms on presentation to hospital bar graph.

London School of Hygiene and Tropical Medicine

Fiona Woo Katherine Atkins Stephane Hue

Phylogenetic modeling to evaluate the role of hospital-acquired infection in sustaining UK transmission

Request for CO-CIN data. For all patients with positive SARS-CoV-2 test and viral sequence from nasal/saliva swab sample. Data variables - employed as healthcare worker, DOB/age, outer postcode, onset data, admission date, readmission?, transfer from other facility? collection date for samples, outcome and date, full lenght viral genome seq for SARS-CoV-2

Investigating variations in the major histocompatibility complex and COVID-19

5-10ml EDTA - intubated/CPAP, <65yrs, no comorbidities. Total of 75 patients. Would require accompanying demographic data

Liverpool University Hospitals Foundation NHS trust and University of Liverpool

Link between Vit D deficiency and at risk groups for severe COVID-19 illness and death.

Plasma or serum (500ul). All patients fom Tier 1, or 500 approx. would require 0.5ml plasma or serum (they have 250 tier 0 patients of their own)

£20 000 funding in place for Vit D assays.

Liverpool School of Tropical Medicine

Ryan Robinson Andrea Collins

Investigate reationship between immunosuppressive treatments and mortality risk of COVID-19 patients.

Immunosuppressive therapy duration and type, demographics, requirement for HDU/ITU admission, mortality rate and duration of inpatient stay.

Trisomy 21 Research Society

Andre Strydom Stephanie Sherman Mara Dierssen

Impact of COVID-19 on individuals with Down Syndrome.

Clinical data incl demographics, co-morbidities, medication,treatment, outcomes etc.

LuMind IDSC Foundation and other Down Syndrome organisations

10.1101/2020.11.03.20225359.

University College London

Investigating differences in the gut microbiome and clinical course of COVID-19

Stool samples (<0.5g) - 1000 (different subsets) and clinical metadata

An intelligent system for the pre-triage of COVID-19 suspected patients based on simple blood exams and data science to benefit resource-poor settings in LMICs.

Clinical data: Demographics, onset and admission, vital signs at admission, co-morbidities, daily lab results, daily treatment, pathogen testing, treatment, outcome.

Queen's University Belfast

Inflammatory signals that can affect microvascular function such as endothelial activation, permeability or intercellular recruitment signals.

Plasma (500ul min); clotted serum (100ul min); blood in blood RNA tube (200ul min). At least 20 depending on variation between disease severity.

Access to samples required to secure funding.

AI tool to generate a neural network to improve diagnosis and predicting prognosis of disease.

Clincal data: demographics, symptoms, lab values and co-morbidities.

Part internally funded, part funded by philanthropy.

The impact of the gut microbiome for the risk/severity of COVID-19, by investigating gut microbiota-derived metabolites using mass spectrometry-based assays.

Serum (250ul) maximum number available at visit 1. Clinical data - demographics, laboratory results, and outcome data.

Funding application dependent on sample approval.

Gut inflammation and the microbiome and adverse patient outcomes

Stool samples (>500mg) as early in disease matched with immunophenotyping data from ISARIC, clinical phenotype and routine lab data.

Internal funding, will apply for external funding with pilot data.

Resubmission as per feedback - Direct RT-qPCR amplification and detection of SARS-CoV-2 from nasal swab eluates, saliva, etc. Working in Emily Adams in LSTM lab.

40 positive combined nose and throat swabs or alone. Preferably from same individual from day 1,3,9 as per protocol or 40 from day 1.

DASA accelerator COVID research program

CRN Yorkshire and Humber

The data is to better understand the relationship between ethnicity and both participation in COVID research as well understanding the impact on individuals from BAME communities.

Access to CRF data - specifically related to ethnicity and outcome measures

Royal Wolverhampton NHS Trust

Srinivisan Venkatachalam

COVID Hyperinflammation study. Use of ISARIC-4C dataset for the Wolverhampton patients to support COVIDHI study.

Clinical characteristics of all COVID patients entered into ISARIC from The Royal Wolverhampton NHS Trust

Data-driven now-casting & fore-casting of health-care resource requirements associated with COVID-19 in Edinburgh and South-East Scotland

CO-CIN data from Tiers 0. 1, 2 from Scotland and rest of UK.

Nottingham Trent University

Prediction of host response to the disease benefit using systems biology approaches

Omics data or biomarker panel data from patients and corresponsding clinical parameters, ethnicity and outcome data.

Duplication of planned work -will share data once available

PCR based identification of SNPS within a host immunity gene and associations between alleles and haplotypes.

PBMCs (cell pellets or DNA) from 250 sever COVID-19 patients and 250 mild cases (matched for age/gender). Patient data on ethnicity and co-morbidities also sought. Also combined nose and throat swab, or extracted DNA from these swabs.

Duplication of planned work -will share data once available

Influence of human glycosylation pathways in COVID-19 clinical outcome

RNA from infected tissues, throat swabs or nasal specimens, Samples from 2 patients groups: mild and severe disease outcomes (10-15 patients per group) Days 1,3,9 and 28. Associated clinical data

Funding for pilot study. Will apply for further funding with IDAMAC support.

Nathalie Signoret Dimitris Lagos

Patients from Yorkshire and Humber - identify correlates of natural immunity, disease development, and recovery. Blood biomarkers of COVID-19 patients with a mixed demographic origin.

Plasma (750ul - 1.5ml) from Tier 1 from adults. Up to 100 depending on availability.

Start with repurposed funding, applying for UKRI rapid response rolling call.

COPD Consortium/Imperial

Paul Cullinan Chloe Bloom Brian Lipworth Thomas Drake Annemarie Docherty

Does inhaled corticosteroid use have an impact on clinical outcomes in patients with COVID-19 disease and either asthma or other chronic respiratory disease; and examindation of UK ISARIC data?

All data from CRF v9.4, all admissions to date of data access; to include relevant measurements in plasma and other biosamples.

Medway NHS Foundation Trust

Determining whether medication taken by patients are protective or limits the prorgress of disease specific to Medway NHS Trust

Site specific data from patients - demographics and all data submitted so far.

Initial review do not need funding, further funding applications if succesful.

Aid diagnosis and prognostic evaluation by using cytokine profiles to distinguish between concurrent outbreaks of influenza and coronavirus

Demographics, outcomes, clinical data and cytokine data

Self-funded, will apply for further funding if succesful

West Hertfordshire Hospitals NHS Trust

Validation cohort for risk prediction study with longer term outcomes called PREDICT COVID.

Data from 5000 patients in population for external validation tool.

Colin Berry Alex McConnachie John Cleland Antonia Ho

Characterise cardiac risk in COVID-19 to guide clinicians on risk stratification and therapy in high-risk groups.

Queen's University Belfast

Screen FDA-approved drugs for antiviral and anti-inflammatory activities in vitro - using viral strains for validation.

Access to 5 anonymised clinical samples (nasal/throat swabs or nasopharyngeal aspirates) from SARS-CoV-2 patients from different geographical locations. Access to 5 low passages (P4) SARS-CoV-2 strains.

UKRI/NIHR COVID-19 Rapid Response

1ug DNA per patient, capacity for over 1000 - application through GenoMICC.

Epsom & St Helier University NHS

Investigating Trust specific nosocomial transmission to assist triaging and cohorting to prevent viral exposure to susceptible patients.

Tier 0 data collected at Epsom & St Heliers

University College London Hospital, NHS Foundation Trust

This is a high resolution, agent based mathematical model developed with the intention of delivering improved capability to model non-pharmaceutical interventions.

These data will be used to inform epidemiological modelling and refine model assumptions.

Test and compare the performance of different mortality prediction scores to support developing countries

Referred to international ISARIC team

Andrew Bretherick, Markus Ralser, Kenneth Baillie

Investigate plasma proteome to inform clinical practice thourgh trajectories and associations, prognostic models of disease outcome and identify novel potential therapeutic targets

40ul EDTA plasma - serial samples n=300. Tier 0 data - genetic data and demographic and clinical information.

T-cell sequencing to identify differences between 'good responders (non-severe) and 'bad responders' (severe) patients to improve treatment outcomes.

1ml of blood in blood RNA tube at day 1,3,9 and 28. Access to metadata - age, sex, disease status and other clinical information.

Duplicates planned analyses

NHS Greater Glasgow & Clyde

We will produce a point of care antibody/immunoassay, building upon our recognised track record of sensitivity equivalence to ELISA demonstrated in serum and time to result <10 mins. We will translate this novel approach for use with SARS-nCoV-19 markers (indicating ongoing infection) and antibodies (indicating past infection). Within four months we will deliver a fully operational prototype validated with clinical COVID-19 samples. Importantly, we have engaged both industrial and clinical collaborators to unlock immediate validation and mass manufacture in Scotland, UK.

15 x 1ml saliva samples from COVID-19 patients. Corresponding data if possible.

Locus specific genotyping of the Fc Gamma locus

Genomic DNA or cell pellets. Minimum of 300ng DNA required. Associated ISARIC clinical data

Ramya Sriskandarajah Sruthi Ramaraju

Dynamic profile of immunological markers which independently predict COVID-19 outcomes

Data from the whole cohort for serum serial levels (day 1,3,9 and 28) for list of biomarkers. Clinical characteristics of patients, demographics, co-morbidities.

London School of Hygiene and Tropical Medicine

Innate and adaptive responses to SARS-CoV-2 infection - T- and B-cell receptor characterisation through deep seq of T/B-Cell receptor VDJ sequences. Multinational dataset - to include samples from Portugal, Brazil, Kenya, and Indonesia

30ml x 20 patients of whole bood (with anticoagulant) at days 1,3,9 and 28. 500ul of sera from 100 patients with range of disease. Metadata

Declined, sample do not exist

University Hospitals North Midlands NHS Trust

Can quantitative (real-time) polymerase chain reaction (PCR) cycle threshold (Ct) values be used to predict poor outcomes for patients infected with SARS-CoV-2?

Compare Ct value from local laboratory database for each patient in local ISARIC-4C dataset

Enhanced surveillance and research of COVID-19 through sharing data with I-MOVE-COVID-19 Consortium to allow Scotland to contribute to a European-level COVID dataset.

Full data collected on all patients on CO-CIN who were hospitalised in Scotland from admission to the current date, and ongoing.

Data is already being provided

University of Sheffield Medical School

Profiling of myeloid cell sub-types, and investigating the dysregulation of their intracellular signalling networks, epigenetic changes and their functional consequences in health vs. disease to identify early markers predictive of the disease progression

24ml whole blood from participants at their local site (Sheffield Teaching Hospitals NHS FT)

Scottish Government Advisory Group - risk of hospitalisation and age.

Age-stratified data for COVID-19 hospitalisations in the UK - national or regional.

Data is already being provided

Investigating variations in the major histocompatibility complex and COVID-19

75 COVID 19 patients who required respiratory support, no significant comorbidities, less than 65 years of age. DNA patients aged 20-50

Mount Sinai Center for Transformative Disease Modeling

Clinical and genetic factors associated with prognosis and response for better patient management and understanding of how some patients survive the disease.

Data only, including patient genetics (SNPs), clinical/demographics data, blood RNA-Seq data, blood immune response data, mucusal response data, and viral load measures.

Year 1: ISMMS seed fund to K.H. Year 2-5: NIH R01 grant (pending).

Duplicates planned analyses will share data when available

Anne McArdle with Ryan Thwaites

Chronic fatigue in COVID-19 survivors and role that pre-existing or newly developed cardiovascular and/or respiratory dysfunction plays and whether cytokine clusters can predict severity of fatigue

Anonymised metadata of participants including age, sex, race, and socio-economic status. Plasma samples (100ul) from up to 104 hospitalised patients for cytokine analysis using Luminex platform. These patients will be retrospectively recruited.Access to routine blood analysis if available.

UKRI funding pending. Pump-priming funds from University of Liverpool for pilot study.

Autoantibodies associated with thrombosis and inflammatory vascular damage - prevalence, specificity, and persistence of the autoantibody response

120ul of plasma from 100 ICU/HDU and 100 non-ICU/HDU COVID-19 patients from Tier 2 @ day 9 of sampling. Work can be carried out with residual samples from PO. Demographics, co-morbidities, clinical presentation, laboratory measurements, treatment outcome.

Imperial College COVID-19 FUND

Royal Devon & Exeter NHS

Access to full ISARIC-4C dataset for site to upload to CAPACITY database

Tier 0 data for Royal Devon & Exeter site

Declined, study leads to engage

The stool samples will be used for the validation of a method we have developed to test SARS-Cov-2 in faecal material.

Stool samples from 10 COVID-19 patients. We need approximately 200 mg /patient.

Pending sample availability

Tom Beneke with Peter Openshaw & Alfredo Castello Palomares

Role of non-infectious SARS-CoV-2 RNA fragments in blood coagulation

Paired serum samples from 52 ISARIC-4C recruits where viral RNA was detected by qPCR (Ct < 37) - 140ul of each sample. If available, 20 paired plasma samples sets from COVID-naive recruits (1ml plasma each).

UKRI funding in process - as soon as confirmation received of sample access.

Royal Free London NHS Foundation Trust

Thomson, Gabriella Captur

plan to enroll patients in an international registry known as CAPACITY-COVID (https://capacity-covid.eu).

complete dataset derived from the Case Report Forms for all patients enrolled at the Royal Free Hospital, London

Processing of the ISARIC data and collection of the CAPACITY-specific fields will be carried out by clinicians with established funding. There will be no additional funding for this work.

Declined, study leads to engage

Royal Devon & Exeter NHS

To look at COVID-19 trends specifically around cardiac complications/past medical history.

Anonymized data from ISARIC to share with the CAPACITY RedCap database.

Declined, study leads to engage

Viyaasan Mahalingasivam

Investigate the long-term effects of COVID-19 on people with CKD to be undertaken at London School of Hygiene and Tropical Medicine.

Summary of how many patients from the ISARIC COVID cohort with/without CKD died and how many survived to discharge, stratified by other baseline characteristics.

Machine Learning and Biomarkers Group

Investigating predictors of COVID kidney - development of AKI, need for renal replacement therapy and long term renal impairment after becoming ill with SARS-CoV-2 infection

Access to the anonymised clinical data of the ISARIC-4C study for research purposes

Risk of death among young Caucasian patients to inform whether a controlled human infection model with COVID-19 can be safely conducted - part of due dilligence

Patients between 20-29 who died of COVID-19. Demographic data - 23 from ISARIC report

Funding pending - Wellcome Trust

CAPACITY Trial/University of Glasgow ICAMS

Rhian Touyz, Colin Berry, Tuuli Hietamies, Katriona Brooksbank

Transfer of ISARIC4C data into the CAPACITY database

BHF Core and CSO grants

Declined, study leads to engage

A Beclere-Saclay University Hospital

Systematic review on neonatal COVID-19 cases

Access to data by Swann et al. Data points: gestational age, birth weight, sex, c-section, 5min APGAR, comorbidities, DOL type of infection (congenital, intrapartum, postpartum)

Anti-inflammatory mediator profiles in patients with mild and severe infections to elucidate anti-inflammatory pathways

5ml blood from COVID-19 patients with severe and mild symptoms

Declined, samples do not exist

Formal assesment of the impact of Remdesivir treatment in COVID-19

Individual level data on persons with a diagnosis of Covid19 and a flag indicating whether they had treatment with Remdesivir or not, and if so dosage data

Have informal approval of funding depending on data being available

COVID-NURSE Clinical Trial (University of Exeter)

Select Trusts with sufficient patient throughput for inclusion in the Covid Nurse trial

Number of patients currently admitted and treated for COVID-19 symptoms in UK NHS Trusts

NIHR/UKRI/MRC; Study Grant Ref: MR/V02776X/1

National Center for Biotechnology, Madrid -Spain

COVID19PATGENOME https://devpost.com/software/covid19patgenome Bioinformatic analysis of genomic data from sequencing of COVID-19 patients that explains severity of this disease and to optimise treatment

Genomic data (FASTQ RNA/DNA files) from COVID-19 patients and their respective clinical data.

Grant funding requested/outstanding

Department of Cardiology, Renmin Hospital of Wuhan University

Test the performance of our CBC score on ISARIC 4C dataset to assess its generalisability to other cohorts, and vice versa, to test and compare ISARIC 4C Score as applied to our Hubei cohort.

Data on 35,463 patients included in the derivation dataset of 4C Score

Grants from Chinese funding bodies

Medical Schooll of Athens

Systematic review and meta-analysis of the incidence of (viral) sepsis (as defined by sepsis-3 criteria), associated with COVID-19. As part of a sepsis awareness initiative in COVID-19. Relevant protocol and design on PROSPERO database (CRD42020202018).

The following data are requested (prioritising the first bullet):
Number of patients with Sequential Organ Failure Assessment (SOFA) score
≥2, consequent to COVID-19 infection
Number of patients with Acute Respiratory Distress Syndrome (ARDS)
Number of patients with Acute Kidney Injury
Number of patients with Acute Kidney Injury
Number of patients requiring vasopressors
Number of patients presenting coagulopathy or Disseminated Intravascular
Coagulation (DIC)
Number of patients with lactate levels >2 mmol/l
Number of patients with mental alterations
Number of patients with bilirubin levels ≥ 1.2 mg/dl or Acute Liver Dysfunction
Number of patients with SOFA score ≥2 who die within the hospital, and number of patients with SOFA score <2 who die within the hospital.

No funding is required for this work.

UCL London Hospitals NHS Foundation Trust

Jessica Manson and Professor Liz Jury

Characterising the pathology underlying COV-HI for stratification of trials with immunomodulatory therapies, and potentially highlight novel therapeutic options

• Serum: 25 patients per group; 500ul serum sample from each at each time point: admission (baseline) and follow-up if available
• Whole blood RNA sequencing data: from 25 patients in Cohort A vs 25 patients in Cohort B.
• If RNA-seq data not available: whole blood RNA from 20 patients per group at Baseline (admission) and follow-up if available
• Accompanying clinical characterisation and laboratory data associated with the samples provided.

5/11/20 (SAMPLE)